
Health technology assessment organizations evaluate medical therapies and technologies to help inform coverage and reimbursement decisions for zzso around the zzso Even as they establish strict review zzso these zzso the reimbursement authorities that use their zzso sometimes handled cancer interventions with special zzso We found that some countries have created separate health technology assessment pathways for cancer treatment, while others have eased access to cancer treatments through zzso or zzso exceptions within health technology assessment zzso In the United States, although no separate evaluation pathways exist for cancer, cancer drugs receive special status by virtue of unique Medicare rules covering zzso zzso Worldwide, we demonstrate that health technology assessment organizations are struggling with zzso zzso 

